You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Junwei Zheng | 920,000 | 0 | 920,000 | 0 | 9.58% |
Page 1 of 5 – SEC Filing
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
SCHEDULE
13D
Under
the Securities Exchange Act of 1934
KIWA
BIO-TECH PRODUCTS GROUP CORPORATION
(Name
of Issuer)
Common
Stock, par value $0.001 per share
(Title
of Class of Securities)
49834X
205
(CUSIP
Number)
Junwei
Zheng
No.
Room 1503
HuichengCommerce
Tower
No.
839, Xiahe Road
Siming
District, Xiamen
Zip
361000, China
(626)
715-5855
(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)
March
31, 2017
(Date
of Event which Requires Filing of this Statement)
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [
]
The
information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
